Search

Wei He

from Seattle, WA
Age ~42
Get Report
Also known as:
He Wei
Related to:
Wei Yan, 38Thomas J Xu, 81Zhen Guang Wang, 58
Connected to:
Baokun He, 49Bo He, 48Bryan D He, 30Camille A He, 45Chenxu He, 46Congzhou He, 52Dajiang He, 71Denis He, 34Diana He, 30Dingshan He, 47

Wei He Phones & Addresses

  • Seattle, WA
  • Issaquah, WA
  • Mercer Island, WA
  • Wilmington, DE
  • Jersey City, NJ

Work

Company: Clifford Chance LLP Address:

Education

School / High School: Cornell Law School

Ranks

Licence: New York - Currently registered Date: 2010

Specialities

M&A Corporate

Professional Records

Lawyers & Attorneys

Wei He Photo 1

Wei He - Lawyer

View page
Address:
Clifford Chance LLP
(106) 535-2288 (Office)
Licenses:
New York - Currently registered 2010
Education:
Cornell Law School
Specialties:
Antitrust / Trade Law - 34%
Arbitration - 33%
Litigation - 33%
Wei He Photo 2

Wei He - Lawyer

View page
Office:
Clifford Chance LLP
Specialties:
M&A Corporate
ISLN:
922090745

Business Records

Name / Title
Company / Classification
Phones & Addresses
Wei Dong He
Director
China Interactive Education, Inc
Wei He
Principal
Hyco International Inc
Nonclassifiable Establishments
9312 138 Ct NE, Redmond, WA 98052

Publications

Us Patents

Quinoline And Quinoxaline Compounds Which Inhibit Platelet-Derived Growth Factor And/Or P56Lck Tyrosine Kinases

View page
US Patent:
62457608, Jun 12, 2001
Filed:
Nov 24, 1998
Appl. No.:
9/198720
Inventors:
Wei He - Collegeville PA
Michael R. Myers - Reading PA
Alfred P. Spada - Lansdale PA
Assignee:
Aventis Pharmaceuticals Products, Inc - Bridgewater NJ
International Classification:
A61K 31498
C07D24140
US Classification:
5142348
Abstract:
This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56. sup. lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Pharmaceutical Compositions And Their Use For Treatment Of Cancer And Autoimmune Diseases

View page
US Patent:
20200323885, Oct 15, 2020
Filed:
Feb 13, 2020
Appl. No.:
16/790197
Inventors:
- Hangzhou, CN
Wei He - Audubon PA, US
Assignee:
ZHEJIANG DTRM BIOPHARMA CO. LTD. - Hangzhou
International Classification:
A61K 31/635
A61K 45/06
A61K 31/519
C07D 487/04
A61P 35/00
A61K 31/52
A61K 31/436
A61K 31/454
Abstract:
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

Methods For Treating Lymphoid Malignancies

View page
US Patent:
20200289517, Sep 17, 2020
Filed:
Oct 26, 2018
Appl. No.:
16/763483
Inventors:
- Hangzhou, Zhejiang Province, CN
Wei He - Audubon PA, US
Assignee:
ZHEJIANG DTRM BIOPHARMA CO. LTD. - Hangzhou, Zhejiang Province
International Classification:
A61K 31/519
A61K 31/436
A61K 31/4439
A61P 35/02
Abstract:
The present disclosure provides methods of treating lymphoid malignancies such as B cell malignancies using a BTK inhibitor in the described therapeutic regimens.

Pharmaceutical Compositions And Their Use For Treatment Of Cancer And Autoimmune Diseases

View page
US Patent:
20190192541, Jun 27, 2019
Filed:
Sep 6, 2018
Appl. No.:
16/123203
Inventors:
- Hangzhou, CN
Wei He - Audubon PA, US
International Classification:
A61K 31/635
C07D 487/04
A61K 31/519
A61K 45/06
A61K 31/454
A61K 31/436
A61K 31/52
A61P 35/00
Abstract:
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

Pharmaceutical Compositions And Their Use For Treatment Of Cancer And Autoimmune Diseases

View page
US Patent:
20180360853, Dec 20, 2018
Filed:
Sep 6, 2018
Appl. No.:
16/123167
Inventors:
- Hangzhou, CN
Wei He - Audubon PA, US
Assignee:
ZHEJIANG DTRM BIOPHARMA CO. LTD. - Hangzhou
International Classification:
A61K 31/635
C07D 487/04
A61K 31/519
A61K 31/436
A61K 45/06
A61P 35/00
A61K 31/454
A61K 31/4162
Abstract:
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

Polyfluorinated Compounds Acting As Bruton Tyrosine Kinase Inhibitors

View page
US Patent:
20180207161, Jul 26, 2018
Filed:
Nov 22, 2017
Appl. No.:
15/820614
Inventors:
- SHANGHAI, CN
Wei He - Audubon PA, US
Assignee:
ZHEJIANG DTRM BIOPHARMA CO. LTD. - SHANGHAI
International Classification:
A61K 31/519
C07F 5/02
C07F 5/04
C07D 519/00
C07D 487/04
C07C 311/08
C07C 303/38
Abstract:
Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

Pharmaceutical Compositions And Their Use For Treatment Of Cancer And Autoimmune Diseases

View page
US Patent:
20170281810, Oct 5, 2017
Filed:
Jun 20, 2017
Appl. No.:
15/628143
Inventors:
- Shanghai, CN
Wei He - Audubon PA, US
International Classification:
A61K 45/06
A61K 31/519
Abstract:
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

Polyfluorinated Compounds Acting As Bruton Tyrosine Kinase Inhibitors

View page
US Patent:
20170065594, Mar 9, 2017
Filed:
Nov 18, 2016
Appl. No.:
15/356014
Inventors:
Wei He - Audubon PA, US
Assignee:
Zhejiang DTRM Biopharma Co. Ltd. - Shanghai
International Classification:
A61K 31/519
Abstract:
Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

Isbn (Books And Publications)

Chun Zhu Ji Wen

View page
Author

Wei He

ISBN #

7101017606

Control profile
Wei He from Seattle, WA, age ~42 Get Report